Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

At Fred Hutch Cancer Center and University of Washington Medical Center, we have an experienced team that provides CRS-HIPEC. Many of our patients receive all their cancer care through Fred Hutch and ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

The boards of directors of Hookipa Pharma (HOOK) and Poolbeg Pharma announced that they have entered into non-binding ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

The study showed that all doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome (CRS) scores, reinforcing its potential in preventing and treating cancer ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

thereby paving the path for dedicated phase 2b trials in these cancer types, with more indications being tested. Given zero CRS toxicity treating patients in an outpatient setting, and substantial ...

Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.